Novel Treatment Combinations Show Promise in Mantle Cell Lymphoma Trials
Key Insights
The ibrutinib/venetoclax combination demonstrated an 83% objective response rate with sustained efficacy in Japanese patients with relapsed/refractory mantle cell lymphoma (search) over 37 months of follow-up.
A novel frontline approach using acalabrutinib/rituximab followed by brexu-cel CAR-T therapy achieved 100% response rates in previously untreated high-risk MCL patients.
Both treatment strategies showed manageable safety profiles despite different toxicity patterns, with the CAR-T approach requiring intensive care in 40% of patients.
Two recent clinical trials have demonstrated encouraging results for novel treatment combinations in mantle cell lymphoma (search) (MCL), offering new therapeutic options for both relapsed/refractory and frontline high-risk disease settings.
Sustained Efficacy with Ibrutinib/Venetoclax in Japanese Patients
The phase 2 M20-075 study evaluated the combination of ibrutinib and venetoclax in 13 Japanese patients with relapsed/refractory MCL, showing sustained long-term efficacy. With a median follow-up of 37.2 months, the combination achieved an objective response rate of 83%, with all responding patients achieving complete responses.
The study demonstrated impressive durability, with a 36-month response rate of 90% and median duration of response not reached. Neither median progression-free survival nor overall survival were reached, with 36-month rates of 69.2% and 76.9%, respectively.
"To date, there is limited availability of data about long-term outcomes in patients with [relapsed/refractory] MCL," noted lead study author Hideki Goto, MD, PhD, from Hokkaido University Hospital. "Considering these results along with the long-term outcomes of M20-075 in Japanese patients, the combination of venetoclax and ibrutinib emerges as a promising treatment option for [relapsed/refractory] MCL in Japan."
The treatment protocol involved ibrutinib at 560 mg orally and venetoclax at 400 mg orally once daily for up to 24 months, followed by ibrutinib alone until disease progression. Patients received venetoclax ramp-up dosing starting at 20 mg with weekly increases to the target dose of 400 mg.
Among patients with minimal residual disease positivity at baseline, 6 of 7 achieved complete responses with undetectable MRD following treatment. The study population had a median age of 71 years, with most patients having relapsed disease and intermediate MCL International Prognostic Index scores.
Frontline CAR-T Approach Shows High Response Rates
The phase 1 Window-3 trial explored a novel frontline approach combining acalabrutinib and rituximab followed by brexucabtagene autoleucel (brexu-cel) CAR-T therapy in 20 patients with previously untreated, high-risk MCL.
The sequential treatment strategy achieved remarkable response rates. After acalabrutinib plus rituximab treatment, the overall response rate was 95%, comprised exclusively of partial responses. Following brexu-cel administration, the response rate improved to 100% at day 30, with 95% of patients achieving complete responses.
"Preclinical studies have shown synergy between BTK (search) inhibition and anti-CD19 (search) CAR T-cell therapy, allowing for improved CAR T-cell expansion, effector functions, and engraftment," explained lead investigator Preetesh Jain, MBBS, MD, DM, PhD, from The University of Texas MD Anderson Cancer Center.
The study population had a median age of 62 years, with 95% having bone marrow involvement and 65% classified as high-risk per MCL International Prognostic Index. Half of the patients had TP53 (search) aberrations, indicating particularly aggressive disease.
At 2 years with a median follow-up of 17 months, both median progression-free survival and overall survival were not reached, with PFS rate of 89% and OS rate of 100%. Undetectable minimal residual disease rates progressively improved, reaching 100% at 12 months and beyond.
Safety Profiles Differ Between Approaches
The safety profiles of the two combinations showed distinct patterns. In the ibrutinib/venetoclax study, all patients experienced adverse events, with 62% having grade 3 or higher events. The most common hematological toxicities included neutropenia (54%), leukopenia (38%), anemia (31%), and thrombocytopenia (31%). Non-hematological events included diarrhea (54%), constipation (38%), and pyrexia (38%).
The CAR-T approach showed different toxicity patterns typical of cellular therapy. All patients experienced cytokine release syndrome, with 5% having grade 3 and 10% having grade 4 CRS. Immune effector cell-associated neurotoxicity syndrome occurred in 75% of patients, with grade 3 in 30% and grade 4 in 15%. Forty percent of patients required intensive care for a median duration of 3 days.
Clinical Implications and Future Directions
Both studies acknowledge limitations including small sample sizes and single-arm designs. The ibrutinib/venetoclax study noted the absence of biomarker testing for TP53 (search) and BTK (search) mutational status, while the Window-3 investigators emphasized the need for extended follow-up and comprehensive translational analyses.
"The study's limited sample size and absence of a control arm constrain definitive attribution of acalabrutinib's effects on CAR [T-cell] fitness and toxicity," Jain noted. "However, extended follow-up with comprehensive translational analyses are currently underway to assess response durability and the impact of acalabrutinib maintenance on [long-term] safety and efficacy."
These findings represent important advances in MCL treatment, addressing the need for effective therapies in both relapsed/refractory and frontline high-risk settings. The sustained responses observed with both approaches suggest potential for improved long-term outcomes in this challenging malignancy.